October 2026—In the never-ending search for new cancer biomarkers, there is always at least one new hopeful waiting in the wings, readying for a potential elevation (so to speak) to star status. Among the latest to generate buzz (at least in the form of oncologists asking about testing) are MTAP deletions. Could these be the latest to have a breakout role? There are many good reasons to think so, says Eric Vail, MD.
October 2026—Antibiotic resistance has changed dramatically. How laboratories detect antibiotic resistant infections and how patients are treated have not. “We treat patients with our best-guess drugs, and we make those guesses based on the types of infections we’re seeing in the patients we take care of and what our local antibiotic resistance rates look like,” says Romney Humphries, PhD, D(ABMM), M(ASCP).
October 2026—This conversation is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with representatives of a company to spotlight its laboratory solutions. He spoke on July 21 with Nick Fingland, PhD, PMP, senior director of R&D operations and science, BD, and Chris Farnsworth, PhD, D(ABCC), section head of clinical chemistry, WashU Medicine, and professor of pathology and immunology and of emergency medicine, Washington University. McGonnagle’s questions and their answers follow. The title of their talk: Where quality begins: the real impact of blood collection choices.
Watch the full conversation:
This roundtable discussion is sponsored by BD.
October 2026—We have all heard the latest claims that the American Medical Association—and the medical specialties it represents—is misusing CPT codes to overpay physicians. Whether these statements come from the Medicare Payment Advisory Commission, members of Congress, or any other group, it’s no wonder we pathologists feel under attack.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: Hematology Analyzers
October 2026—Differential reviews, reference ranges, longitudinal data, AI, and information silos were front and center when CAP TODAY publisher Bob McGonnagle led a discussion online in early September about hematology analyzers and the needs of laboratories and clinicians.
PRODUCT GUIDE ROUNDTABLES
MARKETPLACE
April 2022—The FDA has approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting. The treatment is approved regardless of PD-L1 status and is based on the CheckMate -816 trial, the first positive phase three trial of an immunotherapy-based combination used before surgery for resectable NSCLC.